WHAT'S KNOWN ON THIS SUBJECT: Critical congenital heart disease (CCHD) was recently added to the US Recommended Uniform Screening Panel for newborns.
Critical congenital heart disease (CCHD) was added to the US Recommended Uniform Screening Panel for newborns in 2011. 1 Many states before and since have proposed or approved legislation or regulations requiring CCHD screening at birth hospitals.
CCHD is typically diagnosed prenatally or during postnatal clinical examination. However, newborns with CCHD might not present with signs or symptoms of their condition at birth hospitals. If these newborns leave the birth hospital without a diagnosis, they are at risk for cardiovascular collapse or death. 2 Population-based data from California from 1998 to 2004 suggested at least 0.9 infant deaths per 100 000 live births occurred in the United States due to missed CCHD (calculated from unpublished data obtained from study authors), 3, 4 although authors suggested the number of infants affected by missed CCHD could be much greater. That estimate is equivalent to 36 infant deaths annually in the current US birth cohort. 5 A retrospective analysis of Florida Birth Defects Registry data from 1998 to 2007 estimated 23% (n = 825 in 3603) of infants with CCHD did not receive a diagnosis during their birth hospitalization, of whom 1.8% died before readmission or upon emergency hospital readmission. 6 Recent studies in the United States and Europe indicate CCHD screening through pulse oximetry (a test that measures levels of blood oxygen saturation) can detect CCHD in newborns whose condition is otherwise not apparent at the birth hospital. 7 At present, there is no published economic evaluation of costs and outcomes of newborn CCHD screening in the United States. 8 This study aimed to estimate the cost-effectiveness of screening all US newborns unsuspected of having CCHD.
METHODS

Model
We developed a cohort state transition model using TreeAge Pro 2011 (Williamstown, MA) and Excel software based on available estimates from recent US and European studies (Fig 1) . The model assessed the number of additional newborns with CCHD detected at birth hospitals, number of lives saved, and number of life-years gained from screening. We did not assess quality-adjusted life-years because of a lack of relevant data. We assessed inpatient medical costs from the perspective of the US health care sector. The model' s time horizon was infancy (,1 year of age); therefore, costs were not discounted. All costs are presented as 2011 US dollars. Where necessary, costs were inflated by using annual estimates from the US Producer Price Index for Hospitals. 9 Estimates of life expectancy for the current US birth cohort were discounted at 3%. 10 Model inputs included results from analyses of hospital screening costs in New Jersey in 2012 11 and inpatient costs for infants with CCHD born in Florida from 1998 to 2007, 6 which were undertaken in part to provide information for this analysis (Table 1) .
Clinical Case Definition
CCHD has been defined as congenital heart defects that require surgery or catheter intervention within the first
FIGURE 1
Cohort state transition model of routine screening for CCHD in the United States. year of life. 2 A 2009 article endorsed by the American Heart Association and American Academy of Pediatrics identified a subset of CCHD conditions that present with hypoxemia among newborns as amenable to detection through screening with pulse oximetry at birth hospitals. 2 On the basis of available estimates from recent studies, clinical case criteria for this analysis included 12 screening-detectable CCHD conditions: aortic interruption atresia/hypoplasia, coarctation hypoplasia of the aortic arch, dextotransposition of the great arteries, double-outlet right ventricle, Ebstein anomaly, hypoplastic left heart syndrome, pulmonary atresia (intact septum), single ventricle, tetralogy of Fallot, total anomalous pulmonary venous connection, tricuspid atresia, and truncus arteriosus. Although screening might also detect critical forms of aortic and pulmonary stenosis, we did not include those conditions because administrative diagnostic codes (International Classification of Diseases, Ninth Revision, Clinical Modification) from which we derived clinical information do not distinguish critical forms of those conditions. The 7 conditions identified as primary targets for CCHD screening in the United States are dexto-transposition of the great arteries, hypoplastic left heart syndrome, pulmonary atresia, tetralogy of Fallot, total anomalous pulmonary venous connection, tricuspid atresia, and truncus arteriosus, which mostly or always present with hypoxemia in the newborn period. 12 
Screening Cohort
Our model assessed a scenario in which all newborns unsuspected of having CCHD were screened at US birth hospitals. Nonhospital births were excluded, as were newborns diagnosed through existing pre-or postnatal procedures (referred to here as timely diagnosed) because we assumed they would not be subject to screening. We estimated the prevalence of newborns with late-detected CCHD in the current US hospital birth cohort ( Table 2) . We estimated an annual screening cohort of 3 952 138 newborns, of whom 1534 had CCHD not diagnosed through existing procedures.
Screening Cost
We estimated hospitals' screening cost was $13.50 per newborn based on a recent study in New Jersey, where a legislative mandate for CCHD screening offered an opportunity to collect cost information from a random sample of 7 hospitals. 11 This cost was based on a time and motion study and the US national average hourly wage for registered nurses plus a fringe benefit of 33.2%. Based on a national estimate that 6.7% of newborns are admitted to special/intensive care nurseries per year 13 the estimated screening time per newborn reported in that study, regardless of nursery care facility (eg, well-newborn or special/intensive care), was just over nine minutes. The associated labor and equipment costs per newborn screened were $6.68 and $6.82 (including amortization and maintenance of pulse oximeters and the cost of sensors), respectively, yielding a total estimate of $13.50 per newborn. Only 1 hospital among 7 in the New Jersey evaluation used fully reusable sensors to screen well newborns; therefore, the equipment cost estimate in our base case model primarily reflects the cost of fully or partially disposable screening sensors, which are more expensive than reusable sensors.
Screening Performance and Diagnostic Follow-up
Given the US recommendation to screen newborns after 24 hours of birth, 1 we used screening sensitivity (77.5%) and false-positive rate (0.05%) data from recent meta-analysis for our model based on the results of 7 screening studies (n = 132 361 newborns) conducted $24 hours of birth (Table 1) . 7 CCHD detected among those newborns closely approximated the clinical conditions considered in this analysis, with the exception that some cases of aortic and pulmonary stenosis were detected in the screening performance studies but not included in our analysis due to available data.
We assumed that all newborns who screen positive for CCHD undergo a confirmatory echocardiography examination and that a proportion of those newborns require transportation to another facility for examination and/ or follow-up treatment. The assumption that all newborns with questionable screening results undergo echocardiography may be conservative. It is recommended that newborns with low pulse oximetry readings undergo a full physical examination to rule out other causes of hypoxemia before undergoing an echocardiography; 12 we did not include the costs or outcomes of such testing in our model. A recent analysis of the Florida Birth Defects Registry reported that 43% (n = 1547/ 3603) of newborns with CCHD were transferred during their birth hospitalization. 6 We used this estimate to represent the number of newborns requiring transport to another facility after possible CCHD detection through screening.
Infants with true positive screening results were assigned the cost of an echocardiography with a positive result (eg, a CCHD diagnosis). Infants with false positive screening results were assigned the cost of an echocardiography with a negative result (i.e., no CCHD diagnosis). Infants with false 
Hospitalizations and Mortality
We used available estimates from the published literature to make inferences about the likely experiences of infants detected through routine CCHD screening (Table 1) . On the basis of the Florida Birth Defects Registry study, infants with late-detected CCHD (defined as diagnosis after birth hospital discharge) spent an average of 18% more days in inpatient care compared with infants with timely detected CCHD during the first year of life (44.3 vs 37.5 days). This estimate was adjusted for sociodemographic (eg, race/ethnicity) and clinical factors (eg, CCHD type). We assumed that infants that died during the first year of life would experience half the number of hospitalized days surviving infants did. As noted earlier, an analysis of the Florida Birth Defects Registry reported 1.8% of deaths among infants with late-detected CCHD occurred either outside a hospital following birth hospital discharge or upon emergent hospital readmission after birth hospital discharge. 6 We assumed CCHD detection through screening would eliminate such deaths but not affect other deaths among infants with CCHD.
Sensitivity Analyses
A dearth of previous research on this topic limited our options for sensitivity analysis of the model' s base case assumptions. For this reason, we varied base case estimates by 50% in both directions for most model inputs. In addition, we examined 2 alternate scenarios. In one, we assumed hospitals exclusively used reusable screening sensors for well newborns at a cost of $7.74 per newborn (inclusive of labor and equipment), based on the recent New Jersey study of hospital We first assessed model inputs in isolation through 1-way sensitivity analyses. We then used a probabilistic sensitivity analysis of 1000 simulations in which all model inputs were simultaneously varied within their specified range using triangular probability distributions. We examined probability estimates that screening would be cost-effective at monetary values per life-year that decision makers might consider; specifically, $50 000 and $100 000 per life-year gained. 16 
RESULTS
Base Case
In a hypothetical scenario of routine CCHD screening for US newborns unsuspected of having CCHD, we estimated 1189 more newborns with CCHD would be identified at birth hospitals annually, 20 infant deaths would be averted, and 614 life-years would be gained (Table 3) . We estimated 345 newborns with CCHD would still be discharged from birth hospitals annually without CCHD detection (because screening is not 100% sensitive to detect CCHD), and routine screening would yield 1975 false-positive results.
Without routine screening, the total estimated inpatient cost for CCHD during all of infancy averaged over the entire cohort was $70.32 per infant (Table 3) . With screening, the total estimated average cost for inpatient care, plus screening and associated costs, was $76.59 per infant; hence, an incremental cost of $6.28 per newborn screened. This additional cost consists of screening and confirmatory testing, slightly offset by anticipated savings in inpatient costs during infancy. The estimated cost of false-positive screening results (confirmatory echocardiography and transportation when necessary) constituted a modest 3% ($0.20 per infant screened) of the estimated incremental screening cost per newborn (data not shown).
We estimated an incremental cost of $20 862 per additional newborn with CCHD detected at birth hospitals and $40 385 per life-year gained (Table 3) . Taking into account only the additional cost of screening (without respect to any reduction in hospital treatment costs during infancy as a result of timely detection) the estimated cost per additional newborn with CCHD detected at the birth hospital was $45 724 (data not shown).
Sensitivity Analyses
We tested the influence of each model input in isolation through a series of 1-way sensitivity analyses (Table 4) . On the basis of the primary sensitivity analysis range of 6 50%, we specified that for each model input (Table 1) , the parameters that had the greatest relative influence on the results were as follows: the number of hospitalized days for infants with late-detected CCHD surviving infancy (range for the incremental cost per life-year gained: -$134 614 [cost-saving] to $215 383), the proportion of late detected CCHD among infants with CCHD (range: $11 004 to $108 528), and the hospital cost to screen each newborn (range: -$3052 [costsaving] to $83 821). The parameters that had the least relative influence on the model results were the cost of echocardiography, cost and probability of transport for echocardiography and/or treatment, the mortality rate among infants with screening-detected CCHD, and the false-positive rate.
The alternate 1-way sensitivity analyses indicated reusable sensors and greater mortality improvements could have a substantial impact on the model results. If all hospitals used fully reusable sensors to screen well newborns, we estimated screening would incur just an additional $0.52 per newborn and $3319 per life-year gained (Table 4) . If all deaths among infants with latedetected CCHD were avoided by virtue of screening detection, our model estimated 94 lives would be saved annually (data not shown), at an incremental cost per life-year gained of $10 817 (Table 4) .
The probabilistic sensitivity analysis indicated a 33% chance the incremental cost of screening for CCHD compared with existing clinical practice would be cost-saving; that is, the net cost would be negative. The analysis indicated a 52% chance the incremental cost of screening would be ,$50 000 per life-year gained and a 73% chance the incremental cost of screening would be ,$100 000 per life-year gained (Fig 2) . [21] [22] [23] [24] The Florida Birth Defects Registry is reported to miss up to 15% of birth defects, depending on the defect. 24 We used an overall estimate of 1.8% avoidable mortality among infants with late-detected CCHD based on an analysis of Florida infants, 6 which is equivalent to 28 avoidable deaths among the 1534 infants we estimated have latedetected CCHD in the current US birth cohort. This overall estimate, which does not take into account the fact that mortality among such infants is likely to vary substantially by CCHD type, may be conservative. As previously cited, a California study estimated a minimum of 36 deaths due to missed CCHD in the current birth cohort. 3 A study in Wisconsin from 2002 through 2006 assessed nonhospital and emergency department deaths within 2 weeks of birth among infants with all types of heart disease and reported a higher death rate, the equivalent of 103 deaths in the current US birth cohort. 25 However, that study did not report the total number of infants in the cohort with CCHD as required for our model.
DISCUSSION
Future analyses should go beyond our cost approach to include differences in noninpatient health care costs during and beyond infancy. Comparative data on health care resource utilization among children with CCHD who received timely diagnoses during their newborn period could facilitate a future cost-effectiveness analysis of CCHD screening with a longer time horizon. Such data could also provide additional estimates to refine the sensitivity analysis we presented in this preliminary economic evaluation of routine newborn CCHD screening. A future detailed analysis of mortality among infants with late-detected CCHD could also provide information to further refine model assumptions regarding deaths potentially avoidable through CCHD screening. Our analysis assumed full life expectancy for infants with CCHD who do not die due to late detection of their condition, although life expectancy varies substantially by CCHD type. An additional model extension could include the costs and health benefits of detecting non-CCHD conditions through CCHD screening. A prospective screening study from Sweden noted 45% of newborns with falsepositive results from CCHD screening (ie, newborns with low pulse oximetry readings who did not ultimately receive CCHD diagnoses) had another significant heart malformation, lung problem, or infection. 18 Detecting such conditions through CCHD screening may have added health benefits, which could conceivably lower the overall incremental cost estimates reported here. Incorporating the costs and benefits of detecting non-CCHD conditions in a future cost-effectiveness analysis would, however, require robust, data on the outcomes of such conditions in the absence of CCHD screening.
CONCLUSIONS
Clinical evidence indicates newborn CCHD screening is a lifesaving program. Based on inputs from recent studies, CCHD screening appears costeffective using conventional thresholds and may be cost-saving under some circumstances. We anticipate data from US states that have recently approved or initiated routine CCHD screening will become available over the next few years to refine these projections.
